About the Craniopharyngioma Session
Craniopharyngioma is a rare type of brain tumor, typically benign, but challenging to treat due to its location near critical structures in the brain. Research in cancer treatment for craniopharyngioma focuses on innovative approaches to mitigate side effects and improve outcomes. Novel therapies such as targeted drug delivery systems and immunotherapy are being explored to minimize damage to surrounding tissues while effectively targeting tumor cells. Additionally, advancements in imaging techniques aid in precise tumor localization for surgical removal, reducing the risk of recurrence. Collaborative efforts between clinicians, researchers, and pharmaceutical companies aim to develop personalized treatment strategies tailored to the specific genetic and molecular characteristics of each patient's tumor, offering hope for improved prognosis and quality of life.
Topics Covered in Craniopharyngioma
Adamantinomatous Subtype
Papillary Subtype
BRAF-Targeted Therapy
Endoscopic Endonasal Surgery
Proton Therapy
Endocrine Late Effects
Related Scientific Sessions at CIOC 2027
Why Attend the Craniopharyngioma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Craniopharyngioma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Craniopharyngioma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Craniopharyngioma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Craniopharyngioma Conference 2027 — FAQs
What is the Craniopharyngioma track at CIOC 2027?
The Craniopharyngioma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Craniopharyngioma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Craniopharyngioma sessions?
Cancer researchers and clinicians, educators and students with an interest in Craniopharyngioma are all welcome — whether presenting or attending.
Can I present my research in the Craniopharyngioma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Craniopharyngioma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Craniopharyngioma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.